E-Z-Em to market Pharmacyclics' Gadolite:
This article was originally published in Clinica
Executive Summary
E-Z-Em has obtained exclusive North American marketing rights to Pharmacyclics' MRI oral contrast agent, Gadolite. US FDA approval for use of the agent in abdominal and pelvic imaging will be sought by Pharmacyclics this year. Phase III trials were completed earlier this year (see Clinica No 645, p 22). E-Z-Em, which has the option to negotiate additional marketing rights, will collaborate on development of Gadolite and other products using Pharmacyclics' technology. The two companies will share profits on net sales of Gadolite.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.